
Title:
Furosemide
Text:


Loop diuretic medication
.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}"Lasix" redirects here. For the method of eye surgery, see LASIK.
.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}FurosemideClinical dataPronunciation/fjʊˈroʊsəˌmaɪd/ Trade namesLasix, othersOther namesFrusemideAHFS/Drugs.comMonographMedlinePlusa682858License data
US DailyMed: Furosemide
Pregnancycategory
AU: C

Routes ofadministrationBy mouth, intravenous, intramuscularATC codeC03CA01 (WHO) Legal statusLegal status
AU: S4 (Prescription only) 
UK: POM (Prescription only) 
US: ℞-only 
In general: ℞ (Prescription only)
Pharmacokinetic dataBioavailability43–69%Protein binding91–99%Metabolismliver and kidney glucuronidationOnset of action30 to 60 min (PO), 5 min (IV)[1]Elimination half-lifeup to 100 minutesExcretionKidney 66%, bile duct 33%Identifiers
IUPAC name
4-Chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
CAS Number54-31-9 YPubChem CID3440DrugBankDB00695 YChemSpider3322 YUNII7LXU5N7ZO5KEGGD00331 YChEBICHEBI:47426 YChEMBLChEMBL35 YCompTox Dashboard (EPA)DTXSID6020648 ECHA InfoCard100.000.185 Chemical and physical dataFormulaC12H11ClN2O5SMolar mass330.74 g·mol−13D model (JSmol)Interactive image
SMILES
o1cccc1CNc(cc2Cl)c(C(=O)O)cc2S(=O)(=O)N

InChI
InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19) YKey:ZZUFCTLCJUWOSV-UHFFFAOYSA-N Y
.mw-parser-output .nobold{font-weight:normal}  (verify)
Furosemide is a loop diuretic medication used to treat fluid build-up due to heart failure, liver scarring, or kidney disease.[1] It may also be used for the treatment of high blood pressure.[1] It can be taken by injection into a vein or by mouth.[1] When taken by mouth, it typically begins working within an hour, while intravenously, it typically begins working within five minutes.[1]
Common side effects include feeling lightheaded with standing, ringing in the ears, and sensitivity to light.[1] Potentially serious side effects include electrolyte abnormalities, low blood pressure, and hearing loss.[1] Blood tests are recommended regularly for those on treatment.[1] Furosemide is a type of loop diuretic that works by decreasing the reabsorption of sodium by the kidneys.[1] Common side effects of furosemide injection include hypokalemia (low potassium level), hypotension (low blood pressure), and dizziness.[2]
Furosemide was patented in 1959 and approved for medical use in 1964.[3] It is on the World Health Organization's List of Essential Medicines.[4] In the United States, it is available as a generic medication.[1] In 2019, it was the seventeenth most commonly prescribed medication in the United States, with more than 28 million prescriptions.[5][6] It is on the World Anti-Doping Agency's banned drug list due to concerns that it may mask other drugs.[7] It has also been used in race horses for the treatment and prevention of exercise-induced pulmonary hemorrhage.[8][9]

Contents

1 Medical uses

1.1 Kidney disease
1.2 Other information


2 Adverse effects

2.1 Interactions


3 Mechanism of action
4 Pharmacokinetics
5 Names
6 Veterinary uses

6.1 Horses


7 References
8 Further reading
9 External links



Medical uses[edit]
  Furosemide (Lasix) for injection
Furosemide is primarily used  for the treatment of edema, but also in some cases of hypertension (where there is also kidney or heart impairment).[10] It is often viewed as a first-line agent in most people with edema caused by congestive heart failure because of its anti-vasoconstrictor and diuretic effects.[11][1] Compared with furosemide, however, torasemide has demonstrated to show improvements to heart failure symptoms, possibly lowers the rates of rehospitalisation associated with heart failure and has no difference in risk of death. [12][13][14] Torsemide may also be safer than furosemide.[15][16]
Furosemide is also used for liver cirrhosis, kidney impairment, nephrotic syndrome, in adjunct therapy for swelling of the brain or lungs where rapid diuresis is required (IV injection), and in the management of severe hypercalcemia in combination with adequate rehydration.[17]

Kidney disease[edit]
In chronic kidney diseases with hypoalbuminemia, it is used along with albumin to increase diuresis.[18] It is also used along with albumin in nephrotic syndrome to reduce edema.[19]

Other information[edit]
It is mainly excreted by tubular secretion in the kidney. In kidney impairment, clearance is reduced, increasing the risk of adverse effects.[1]  Lower initial doses are recommended in older patients (to minimize side-effects) and high doses may be needed in kidney failure.[20] It can also cause kidney damage; this is mainly by loss of excessive fluid (i.e. dehydration), and is usually reversible.
Furosemide acts within 1 hour of oral administration (after IV injection, the peak effect is within 30 minutes). Diuresis is usually complete within 6–8 hours of oral administration, but there is significant variation between individuals.[21]
Adverse effects[edit]
Furosemide also can lead to gout caused by hyperuricemia. Hyperglycemia is also a common side effect.
The tendency, as for all loop diuretics, to cause low serum potassium concentration (hypokalemia) has given rise to combination products, either with potassium or with the potassium-sparing diuretic amiloride (Co-amilofruse). Other electrolyte abnormalities that can result from furosemide use include hyponatremia, hypochloremia, hypomagnesemia, and hypocalcemia.[22]
In the treatment of heart failure, many studies have shown that the long-term use of furosemide can cause varying degrees of thiamine deficiency, so thiamine supplementation is also suggested.[23]
Furosemide is a known ototoxic agent generally causing transient hearing loss but can be permanent. Reported cases of furosemide induced hearing loss appeared to be associated with rapid intravenous administration, high dosages, concomitant renal disease and coadministration with other ototoxic medication.[24][25] However, a recently reported longitudinal study showed that participants treated with loop diuretics over 10 years were 40% more likely to develop hearing loss and 33% more likely of progressive hearing loss compared to participants who did not use loop diuretics.[26] This suggests the long-term consequences of loop diuretics on hearing could be a more significant than previously thought and further research is required in this area.  
Other precautions include: nephrotoxicity, sulfonamide (sulfa) allergy, and increases free thyroid hormone effects with large doses.[27]

Interactions[edit]
Furosemide has potential interactions with these medications:[28]

Aspirin and other salicylates
Other diuretics (e.g. ethacrynic acid, hydrochlorothiazide)
Synergistic effects with other antihypertensives (e.g. doxazosin)
Sucralfate
Potentially hazardous interactions with other drugs:

Analgesics: increased risk of kidney damage (nephrotoxicity) with nonsteroidal anti-inflammatory drugs; antagonism of diuretic effect with NSAIDs
Antiarrhythmics: a risk of cardiac toxicity exists with antiarrhythmics if hypokalemia occurs; the effects of lidocaine and mexiletine are antagonized.
Antibacterials: increased risk of ototoxicity with aminoglycosides, polymyxins and vancomycin; avoid concomitant use with lymecycline
Antidepressants: increased risk of hypokalemia with reboxetine; enhanced hypotensive effect with MAOIs; increased risk of postural hypotension with tricyclic antidepressants
Antiepileptics: increased risk of hyponatremia with carbamazepine
Antifungals: increased risk of hypokalemia with amphotericin
Antihypertensives: enhanced hypotensive effect; increased risk of first dose hypotensive effect with alpha-blockers; increased risk of ventricular arrhythmias with sotalol if hypokalemia occurs
Antipsychotics: increased risk of ventricular arrhythmias with amisulpride, sertindole, or pimozide (avoid with pimozide) if hypokalemia occurs; enhanced hypotensive effect with phenothiazines
Atomoxetine: hypokalemia increases risk of ventricular arrhythmias
Cardiac glycosides: increased toxicity if hypokalemia occurs
Cyclosporine: variable reports of increased nephrotoxicity, ototoxicity and hepatotoxicity
Lithium: risk of toxicity.
Mechanism of action[edit]
Main article: Loop diuretic
Furosemide, like other loop diuretics, acts by inhibiting the luminal Na-K-Cl cotransporter in the thick ascending limb of the loop of Henle, by binding to the chloride transport channel, thus causing more sodium, chloride, and potassium to stay in the urine.[29]
The action on the distal tubules is independent of any inhibitory effect on carbonic anhydrase or aldosterone; it also abolishes the corticomedullary osmotic gradient and blocks negative, as well as positive, free water clearance. Because of the large NaCl absorptive capacity of the loop of Henle, diuresis is not limited by development of acidosis, as it is with the carbonic anhydrase inhibitors.
Additionally, furosemide is a noncompetitive subtype-specific blocker of GABA-A receptors.[30][31][32] Furosemide has been reported to reversibly antagonize GABA-evoked currents of α6β2γ2 receptors at μM concentrations, but not α1β2γ2 receptors.[30][32] During development, the α6β2γ2 receptor increases in expression in cerebellar granule neurons, corresponding to increased sensitivity to furosemide.[31]

Pharmacokinetics[edit]
Molecular weight (daltons)             330.7
% Bioavailability    47-70%
Bioavailability with end-stage renal disease   43 - 46%[33][34]
% Protein binding                      91–99[35]
Volume of distribution (L/kg)          0.07 – 0.2[36][37]
Volume of distribution may be higher in patients with cirrhosis or nephrotic syndrome[36]
Excretion
% Excreted in urine (% of total dose)   60 - 90[36][37]
% Excreted unchanged in urine (% of total dose)         53.1 - 58.8 [38]
% Excreted in feces (% of total dose)  7 - 9[21]
% Excreted in bile (% of total dose) 6 - 9[37]
Approximately 10% is metabolized by the liver in healthy individuals, but this percentage may be greater in individuals with severe kidney failure [37]
Renal clearance (mL/min/kg)  2.0[36]
Elimination half-life (hrs)   2[35]
Prolonged in congestive heart failure (mean 3.4 hrs)[36][39]
Prolonged in severe kidney failure (4 - 6 hrs)[40] and anephric patients (1.5-9 hrs)[37]
Time to peak concentration (hrs)
Intravenous administration    0.3[41]
Oral solution    0.83[35]
Oral tablet     1.45[35]
The pharmacokinetics of furosemide are apparently not significantly altered by food.[42]
No direct relationship has been found between furosemide concentration in the plasma and furosemide efficacy. Efficacy depends upon the concentration of furosemide in urine.[21]

Names[edit]
Furosemide is the INN and BAN.[43] The previous BAN was frusemide.
Brand names under which furosemide is marketed include: Aisemide, Apo-Furosemide, Beronald, Desdemin, Discoid, Diural, Diurapid, Dryptal, Durafurid, Edemid, Errolon, Eutensin, Flusapex, Frudix, Frusemide, Frusetic, Frusid, Fulsix, Fuluvamide, Furesis, Furix, Furo-Puren, Furon, Furosedon, Fusid.frusone, Hydro-rapid, Impugan, Katlex, Lasilix, Lasix, Lodix, Lowpston, Macasirool, Mirfat, Nicorol, Odemase, Oedemex, Profemin, Rosemide, Rusyde, Salix, Seguril, Teva-Furosemide, Trofurit, Uremide, and Urex.

Veterinary uses[edit]
The diuretic effects are put to use most commonly in horses to prevent bleeding during a race. Sometime in the early 1970s, furosemide's ability to prevent, or at least greatly reduce, the incidence of bleeding (exercise-induced pulmonary hemorrhage) by horses during races was discovered accidentally.  In the United States of America, pursuant to the racing rules of most states, horses that bleed from the nostrils three times are permanently barred from racing. Clinical trials followed, and by decade's end, racing commissions in some states in the USA began legalizing its use on race horses.  In 1995, New York became the last state in the United States to approve such use, after years of refusing to consider doing so.[44] Some states allow its use for all racehorses; some allow it only for confirmed "bleeders".  Its use for this purpose is still prohibited in many other countries.
Furosemide is also used in horses for pulmonary edema, congestive heart failure (in combination with other drugs), and allergic reactions.  Although it increases circulation to the kidneys, it does not help kidney function, and is not recommended for kidney disease.[45]
It is also used to treat congestive heart failure (pulmonary edema, pleural effusion, and/or ascites) in cats and dogs.[46] It can also be used in an attempt to promote urine production in anuric or oliguric acute kidney failure.

Horses[edit]
Furosemide is injected either intramuscularly or intravenously, usually 0.5-1.0 mg/kg twice/day, although less before a horse is raced. As with many diuretics, it can cause dehydration and electrolyte imbalance, including loss of potassium, calcium, sodium, and magnesium. Excessive use of furosemide will most likely lead to a metabolic alkalosis due to hypochloremia and hypokalemia. The drug should, therefore, not be used in horses that are dehydrated or experiencing kidney failure. It should be used with caution in horses with liver problems or electrolyte abnormalities. Overdose may lead to dehydration, change in drinking patterns and urination, seizures, gastrointestinal problems, kidney damage, lethargy, collapse, and coma.
Furosemide should be used with caution when combined with corticosteroids (as this increases the risk of electrolyte imbalance), aminoglycoside antibiotics (increases risk of kidney or ear damage), and trimethoprim sulfa (causes decreased platelet count). It may also cause interactions with anesthetics, so its use should be related to the veterinarian if the animal is going into surgery, and it decreases the kidneys' ability to excrete aspirin, so dosages will need to be adjusted if combined with that drug.
Furosemide may increase the risk of digoxin toxicity due to hypokalemia.
The drug is best not used during pregnancy or in a lactating mare, as it has been shown to be passed through the placenta and milk in studies with other species. It should not be used in horses with pituitary pars intermedia dysfunction (Cushings).
Furosemide is detectable in urine 36–72 hours following injection. Its use is restricted by most equestrian organizations.
In April 2019, it was announced that Lasix would be banned from use at US racetracks within 24 hours of a horse racing starting in 2021.[47]

References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ a b c d e f g h i j k l .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"Furosemide". The American Society of Health-System Pharmacists. Archived from the original on 19 November 2015. Retrieved 23 October 2015.

^ "Coronavirus (COVID-19) Update: December 22, 2020". U.S. Food and Drug Administration (Press release). 22 December 2020. Retrieved 22 December 2020.  This article incorporates text from this source, which is in the public domain.

^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 458. ISBN 9783527607495.

^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

^ "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021.

^ "Furosemide - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021.

^ "THE 2014 PROHIBITED LIST INTERNATIONAL STANDARD" (PDF). 2014. p. 5. Archived (PDF) from the original on 15 January 2016. Retrieved 24 October 2015.

^ Sullivan S, Hinchcliff K (April 2015). "Update on exercise-induced pulmonary hemorrhage". The Veterinary Clinics of North America. Equine Practice. 31 (1): 187–98. doi:10.1016/j.cveq.2014.11.011. PMID 25770069.

^ Hinchcliff KW, Couetil LL, Knight PK, Morley PS, Robinson NE, Sweeney CR, van Erck E (2015). "Exercise induced pulmonary hemorrhage in horses: American College of Veterinary Internal Medicine consensus statement". Journal of Veterinary Internal Medicine. 29 (3): 743–58. doi:10.1111/jvim.12593. PMC 4895427. PMID 25996660.

^ "Furosemide". The American Society of Health-System Pharmacists. Archived from the original on 17 March 2011. Retrieved 3 April 2011.

^ King, Kevin C.; Goldstein, Samuel (2021), "Congestive Heart Failure And Pulmonary Edema", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32119444, retrieved 8 May 2021

^ Täger T, Fröhlich H, Seiz M, Katus HA, Frankenstein L (March 2019). "READY: relative efficacy of loop diuretics in patients with chronic systolic heart failure-a systematic review and network meta-analysis of randomised trials". Heart Fail Rev. 24 (4): 461–472. doi:10.1007/s10741-019-09771-8. PMID 30874955. S2CID 77394851.

^ Miles JA, Hanumanthu BK, Patel K, Chen M, Siegel RM, Kokkinidis DG (June 2019). "Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis". J Cardiovasc Med (Hagerstown). 20 (6): 379–388. doi:10.2459/JCM.0000000000000794. PMID 30950982. S2CID 96436158.

^ Abraham, Bishoy; Megaly, Michael; Sous, Mina; Fransawyalkomos, Mina; Saad, Marwan; Fraser, Robert; Topf, Joel; Goldsmith, Steven; Simegn, Mengistu; Bart, Bradley; Azzo, Zain (1 January 2020). "Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure". American Journal of Cardiology. 125 (1): 92–99. doi:10.1016/j.amjcard.2019.09.039. ISSN 0002-9149. PMID 31699358.

^ Roush GC, Kaur R, Ernst ME (2014). "Diuretics: a review and update". J. Cardiovasc. Pharmacol. Ther. 19 (1): 5–13. doi:10.1177/1074248413497257. PMID 24243991.

^ Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM (2015). "A reappraisal of loop diuretic choice in heart failure patients". Am. Heart J. 169 (3): 323–33. doi:10.1016/j.ahj.2014.12.009. PMC 4346710. PMID 25728721.

^ Rossi S, ed. (2004). Australian Medicines Handbook 2004 (5th ed.). Adelaide, S.A.: Australian Medicines Handbook Pty Ltd. ISBN 978-0-9578521-4-3.

^ Kitsios GD, Mascari P, Ettunsi R, Gray AW (April 2014). "Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: a meta-analysis". Journal of Critical Care. 29 (2): 253–9. doi:10.1016/j.jcrc.2013.10.004. PMID 24268626.

^ Duffy M, Jain S, Harrell N, Kothari N, Reddi AS (October 2015). "Albumin and Furosemide Combination for Management of Edema in Nephrotic Syndrome: A Review of Clinical Studies". Cells. 4 (4): 622–30. doi:10.3390/cells4040622. PMC 4695849. PMID 26457719.

^ "British National Formulary". Retrieved 9 November 2018.

^ a b c Ponto LL, Schoenwald RD (May 1990). "Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I)". Clinical Pharmacokinetics. 18 (5): 381–408. doi:10.2165/00003088-199018050-00004. PMID 2185908. S2CID 32352501.

^ Oh SW, Han SY (June 2015). "Loop Diuretics in Clinical Practice". Electrolyte & Blood Pressure. 13 (1): 17–21. doi:10.5049/EBP.2015.13.1.17. PMC 4520883. PMID 26240596.

^ Katta N, Balla S, Alpert MA (July 2016). "Does Long-Term Furosemide Therapy Cause Thiamine Deficiency in Patients with Heart Failure? A Focused Review". The American Journal of Medicine. 129 (7): 753.e7–753.e11. doi:10.1016/j.amjmed.2016.01.037. PMID 26899752.

^ Favrelière S, Delaunay P, Lebreton JP, Rouby F, Atzenhoffer M, Lafay-Chebassier C, Pérault-Pochat MC (June 2020). "Drug-induced hearing loss: a case/non-case study in the French pharmacovigilance database". Fundamental & Clinical Pharmacology. 34 (3): 397–407. doi:10.1111/fcp.12533. PMID 31912913. S2CID 210087413.

^ Gallagher KL, Jones JK (November 1979). "Furosemide-induced ototoxicity". Annals of Internal Medicine. 91 (5): 744–5. doi:10.7326/0003-4819-91-5-744. PMID 496112.

^ Joo Y, Cruickshanks KJ, Klein BE, Klein R, Hong O, Wallhagen MI (February 2020).  Newman A (ed.). "The Contribution of Ototoxic Medications to Hearing Loss Among Older Adults". The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 75 (3): 561–566. doi:10.1093/gerona/glz166. PMC 7328195. PMID 31282945.

^ "UpToDate". www.uptodate.com. Retrieved 6 November 2018.

^ Brand name:Lasix - Generic name: Furosemide Prescription Drug Information, Side Effects - PDRHealth

^ Dowd FJ, Johnson B, Mariotti A (3 September 2016). Pharmacology and Therapeutics for Dentistry - E-Book. Elsevier Health Sciences. pp. 324–326. ISBN 9780323445955. Retrieved 4 November 2017.

^ a b Korpi ER, Kuner T, Seeburg PH, Lüddens H (1995). "Selective antagonist for the cerebellar granule cell-specific gamma-aminobutyric acid type A receptor". Mol. Pharmacology. 47 (2): 283–9. PMID 7870036.

^ a b Tia S, Wang JF, Kotchabhakdi N, Vicini S (1996). "Developmental changes of inhibitory synaptic currents in cerebellar granule neurons: role of GABA(A) receptor alpha 6 subunit". J. Neurosci. 16 (11): 3630–40. doi:10.1523/JNEUROSCI.16-11-03630.1996. PMC 6578841. PMID 8642407.

^ a b Wafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS, Whiting PJ (1996). "Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit". Mol. Pharmacol. 50 (3): 670–8. PMID 8794909.

^ AMA Department of Drugs: Drug Evaluations Subscription, American Medical Association, Chicago, IL, 1990.

^ Knoben JE & Anderson PO (Eds): Handbook of Clinical Drug Data, 6th. Drug Intelligence Publications, Inc, Hamilton, IL, 1988.

^ a b c d Product Information: Lasix(R), furosemide. Aventis Pharmaceuticals, Bridgewater, NJ, 2004.

^ a b c d e Gilman AG, Rall TW, Nies AS, et al (Eds): Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th. Pergamon Press, New York, NY, 1990.

^ a b c d e Kelly MR, Cutler RE, Forrey AW, Kimpel BM (February 1974). "Pharmacokinetics of orally administered furosemide". Clinical Pharmacology and Therapeutics. 15 (2): 178–86. doi:10.1002/cpt1974152178. PMID 4812154. S2CID 74223978.

^ Verbeeck RK, Patwardhan RV, Villeneuve JP, Wilkinson GR, Branch RA (June 1982). "Furosemide disposition in cirrhosis". Clinical Pharmacology and Therapeutics. 31 (6): 719–25. doi:10.1038/clpt.1982.101. PMID 7075120. S2CID 27659838.

^ Chaturvedi PR, O'Donnell JP, Nicholas JM, Shoenthal DR, Waters DH, Gwilt PR (March 1987). "Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure". International Journal of Clinical Pharmacology, Therapy, and Toxicology. 25 (3): 123–8. PMID 3557737.

^ Brater DC (1991). "Clinical pharmacology of loop diuretics". Drugs. 41 Suppl 3 (Supplement 3): 14–22. doi:10.2165/00003495-199100413-00004. PMID 1712712. S2CID 41247401.

^ Haegeli L, Brunner-La Rocca HP, Wenk M, Pfisterer M, Drewe J, Krähenbühl S (December 2007). "Sublingual administration of furosemide: new application of an old drug". British Journal of Clinical Pharmacology. 64 (6): 804–9. doi:10.1111/j.1365-2125.2007.03035.x. PMC 2198789. PMID 17875188.

^ AHFS Drug Information 2004. McEvoy GK, ed. Furosemide. American Society of Health-System Pharmacists; 2004: 2260-4.

^ "Naming human medicines". Archived from the original on 27 April 2010. Retrieved 18 November 2009.

^ "COMMENTARY : New York Buckles and Allows Lasix Use". 28 May 1995. Retrieved 22 January 2022.

^ "https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1939-1676.1991.tb00951.x". January 2022. {{cite web}}: External link in |title= (help)

^ Kittleson M, Kienle R (1998). Small Animal Cardiovascular Medicine. ISBN 978-0-8151-5140-1.

^ "U.S. Racetracks to ban race-day Lasix in 2021". 18 April 2019.


Further reading[edit]
Aventis Pharma (1998). Lasix Approved Product Information. Lane Cove: Aventis Pharma Pty Ltd.
Barbara Forney (2007). Understanding Equine Medications, Revised Edition (Horse Health Care Library). Eclipse Press. ISBN 978-1-58150-151-3.
External links[edit]
"Furosemide". Drug Information Portal. U.S. National Library of Medicine.
"Furosemide Injection". MedlinePlus.
Lasix and horse bleeding
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteDiuretics (C03)Sulfonamides(and etacrynic acid)CA inhibitors (at PT)
Acetazolamide
Loop (Na-K-Cl at AL)
Furosemide#
Azosemide
Bumetanide
Etacrynic acid
Etozolin
Indacrinone
Muzolimine
Ozolinone
Piretanide
Tienilic acid
Torasemide
Thiazides (Na-Cl at DCT,Calcium-sparing)
Altizide
Bendroflumethiazide
Butizide
Chlorothiazide
Cyclopenthiazide
Cyclothiazide
Epitizide
Hydrochlorothiazide#
Hydroflumethiazide
Mebutizide
Methyclothiazide
Polythiazide
Trichlormethiazide
Thiazide-likes (primarily DCT)
Quinethazone
Clopamide
Chlortalidone
Mefruside
Clofenamide
Metolazone
Meticrane
Xipamide
Indapamide
Clorexolone
Fenquizone
Potassium-sparing (at CD)ESC blockers
Amiloride#
Triamterene
Benzamil
Aldosterone antagonists
Spirolactones
Spironolactone#
Eplerenone
Potassium canrenoate
Canrenone
Nonsteroidal
Finerenone
Osmotic diuretics (PT, DL)
Mannitol#
Glycerol
Urea
Vasopressin receptor inhibitors(DCT and CD)
Vaptans
Conivaptan
Mozavaptan
Satavaptan
Tolvaptan
Others
Demeclocycline
Lithium carbonate
Other
Ethanol, Isopropanol, 2M2B
mercurial diuretics (Chlormerodrin, Mersalyl, Meralluride)
Theobromine
Cicletanine
Combination products
Hydrochlorothiazide/triamterene

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

Pharmacodynamics
vteGABA receptor modulatorsIonotropicGABAA
Agonists: (+)-Catechin
Bamaluzole
Barbiturates (e.g., phenobarbital)
Beta-Alanine
BL-1020
DAVA
Dihydromuscimol
GABA
Gabamide
GABOB
Gaboxadol (THIP)
Homotaurine (tramiprosate, 3-APS)
Ibotenic acid
iso-THAZ
iso-THIP
Isoguvacine
Isomuscimol
Isonipecotic acid
Kojic amine
L-838,417
Lignans (e.g., honokiol)
Methylglyoxal
Monastrol
Muscimol
Nefiracetam
Neuroactive steroids (e.g., allopregnanolone)
Org 20599
PF-6372865
Phenibut
Picamilon
P4S
Progabide
Propofol
Quisqualamine
SL-75102
Taurine
TACA
TAMP
Terpenoids (e.g., borneol)
Thiomuscimol
Tolgabide
ZAPA
Positive modulators (abridged; see here for a full list): α-EMTBL
Alcohols (e.g., drinking alcohol, 2M2B)
Anabolic steroids
Avermectins (e.g., ivermectin)
Barbiturates (e.g., phenobarbital)
Benzodiazepines (e.g., diazepam)
Bromide compounds (e.g., potassium bromide)
Carbamates (e.g., meprobamate)
Carbamazepine
Chloralose
Chlormezanone
Clomethiazole
Dihydroergolines (e.g., ergoloid (dihydroergotoxine))
Etazepine
Etifoxine
Fenamates (e.g., mefenamic acid)
Flavonoids (e.g., apigenin, hispidulin)
Fluoxetine
Flupirtine
Imidazoles (e.g., etomidate)
Kava constituents (e.g., kavain)
Lanthanum
Loreclezole
Monastrol
Neuroactive steroids (e.g., allopregnanolone, cholesterol, THDOC)
Niacin
Niacinamide
Nonbenzodiazepines (e.g., β-carbolines (e.g., abecarnil), cyclopyrrolones (e.g., zopiclone), imidazopyridines (e.g., zolpidem), pyrazolopyrimidines (e.g., zaleplon))
Norfluoxetine
Petrichloral
Phenols (e.g., propofol)
Phenytoin
Piperidinediones (e.g., glutethimide)
Propanidid
Pyrazolopyridines (e.g., etazolate)
Quinazolinones (e.g., methaqualone)
Retigabine (ezogabine)
ROD-188
Skullcap constituents (e.g., baicalin)
Stiripentol
Sulfonylalkanes (e.g., sulfonmethane (sulfonal))
Topiramate
Valerian constituents (e.g., valerenic acid)
Volatiles/gases (e.g., chloral hydrate, chloroform, diethyl ether, paraldehyde, sevoflurane)
Antagonists: Bicuculline
Coriamyrtin
Dihydrosecurinine
Gabazine (SR-95531)
Hydrastine
Hyenachin (mellitoxin)
PHP-501
Pitrazepin
Securinine
Sinomenine
SR-42641
SR-95103
Thiocolchicoside
Tutin
Negative modulators: 1,3M1B
3M2B
11-Ketoprogesterone
17-Phenylandrostenol
α5IA (LS-193,268)
β-CCB
β-CCE
β-CCM
β-CCP
β-EMGBL
Anabolic steroids
Amiloride
Anisatin
β-Lactams (e.g., penicillins, cephalosporins, carbapenems)
Basmisanil
Bemegride
Bicyclic phosphates (TBPS, TBPO, IPTBO)
BIDN
Bilobalide
Bupropion
CHEB
Chlorophenylsilatrane
Cicutoxin
Cloflubicyne
Cyclothiazide
DHEA
DHEA-S
Dieldrin
(+)-DMBB
DMCM
DMPC
EBOB
Etbicyphat
FG-7142 (ZK-31906)
Fiproles (e.g., fipronil)
Flavonoids (e.g., amentoflavone, oroxylin A)
Flumazenil
Fluoroquinolones (e.g., ciprofloxacin)
Flurothyl
Furosemide
Golexanolone
Iomazenil (123I)
IPTBO
Isopregnanolone (sepranolone)
L-655,708
Laudanosine
Leptazol
Lindane
MaxiPost
Morphine
Morphine-3-glucuronide
MRK-016
Naloxone
Naltrexone
Nicardipine
Nonsteroidal antiandrogens (e.g., apalutamide, bicalutamide, enzalutamide, flutamide, nilutamide)
Oenanthotoxin
Pentylenetetrazol (pentetrazol)
Phenylsilatrane
Picrotoxin (i.e., picrotin, picrotoxinin and dihydropicrotoxinin)
Pregnenolone sulfate
Propybicyphat
PWZ-029
Radequinil
Ro 15-4513
Ro 19-4603
RO4882224
RO4938581
Sarmazenil
SCS
Suritozole
TB-21007
TBOB
TBPS
TCS-1105
Terbequinil
TETS
Thujone
U-93631
Zinc
ZK-93426
GABAA-ρ
Agonists: BL-1020
CACA
CAMP
Homohypotaurine
GABA
GABOB
Ibotenic acid
Isoguvacine
Muscimol
N4-Chloroacetylcytosine arabinoside
Picamilon
Progabide
TACA
TAMP
Thiomuscimol
Tolgabide
Positive modulators: Allopregnanolone
Alphaxolone
ATHDOC
Lanthanides
Antagonists: (S)-2-MeGABA
(S)-4-ACPBPA
(S)-4-ACPCA
2-MeTACA
3-APMPA
4-ACPAM
4-GBA
cis-3-ACPBPA
CGP-36742 (SGS-742)
DAVA
Gabazine (SR-95531)
Gaboxadol (THIP)
I4AA
Isonipecotic acid
Loreclezole
P4MPA
P4S
SKF-97541
SR-95318
SR-95813
TPMPA
trans-3-ACPBPA
ZAPA
Negative modulators: 5α-Dihydroprogesterone
Bilobalide
Loreclezole
Picrotoxin (picrotin, picrotoxinin)
Pregnanolone
ROD-188
THDOC
Zinc
MetabotropicGABAB
Agonists: 1,4-Butanediol
3-APPA
4-Fluorophenibut
Aceburic acid
Arbaclofen
Arbaclofen placarbil
Baclofen
BL-1020
GABA
Gabamide
GABOB
GBL
GHB
GHBAL
GHV
GVL
Isovaline
Lesogaberan
Phenibut
Picamilon
Progabide
Sodium oxybate
SKF-97,541
SL 75102
Tolgabide
Tolibut
Positive modulators: ADX-71441
BHF-177
BHFF
BSPP
CGP-7930
CGP-13501
GS-39783
rac-BHFF
KK-92A
Antagonists: 2-Hydroxysaclofen
CGP-35348
CGP-46381
CGP-52432
CGP-54626
CGP-55845
CGP-64213
DAVA
Homotaurine (tramiprosate, 3-APS)
Phaclofen
Saclofen
SCH-50911
SKF-97541
Negative modulators: Compound 14

See also
Receptor/signaling modulators 
GABAA receptor positive modulators 
GABA metabolism/transport modulators 

vteGlutamate metabolism and transport modulatorsTransporterEAATs
Amphetamine
Aspartic acid (aspartate)
cis-ACBD
DHKA
Glutamic acid (glutamate)
HIP-A
HIP-B
Kainic acid
L-(-)-threo-3-Hydroxyaspartic acid
L-αAA
L-CCG-III ((2S,3S,4R)-CCG)
L-Serine-O-sulphate (SOS)
L-trans-2,4-PDC
MPDC
Maslinic acid
SYM-2081
TBOA
TFB-TBOA
Theanine
threo-3-Methylglutamic acid
UCPH-101
WAY-213,613
vGluTs
4-Methylene-L-glutamate
6-(4'-Phenylstyryl)-QDC
6-Biphenyl-4-yl-QDC
7-CKA
Acid red 114
Amido black 10B (naphthol blue black)
Bafilomycin A1
Benzopurpurin 4B
Bumetamide
Chicago sky blue 6B
Aspartic acid (aspartate)
DIDS
Direct blue 71
Erythro-4-methyl-L-glutamic acid
Evans blue
Furosemide
Glutamic acid (glutamate)
Kynurenic acid
Nigericin
NPPB (N144)
Ponceau SS
Reactive blue 2
Rose bengal
SITS
trans-ACDP
Trypan blue
Valinomycin
Xanthurenic acid
EnzymeGAH
BPTES
CB-839
DON
AST
2-Amino-3-butenoic acid
AAOA
AMB
β-DL-Methylene-aspartate
Hydrazinosuccinate
ALT
β-Chloro-L-alanine
L-Cycloserine
Propargylglycine
GDH
AAOA
Bithionol
Chloroquine
EGCG
GTP
GW5074
Hexachlorophene
Hydroxylamine
Palmitoyl-CoA
Pyridoxal phosphate
GS
2-Aminoadipic acid
JFD01307SC
Methionine sulfoximine
Phosphinothricin (glufosinate)
GAD
3-Mercaptopropionic acid
AAOA
L-Allylglycine
Semicarbazide
See also: Receptor/signaling modulators • Ionotropic glutamate receptor modulators • Metabotropic glutamate receptor modulators • GABA metabolism and transport modulators
vteGlycine receptor modulatorsReceptor(ligands)GlyR
Agonists: β-Alanine
β-ABA (BABA)
β-AIBA
Caesium
D-Alanine
D-Serine
GABA
Glycine
Hypotaurine
Ivermectin
L-Alanine
L-Proline
L-Serine
L-Threonine
MDL-27531
Milacemide
Picolinic acid
Propofol
Quisqualamine
Sarcosine
Taurine
Positive modulators: Alcohols (e.g., brometone, chlorobutanol (chloretone), ethanol (alcohol), tert-butanol (2M2P), tribromoethanol, trichloroethanol, trifluoroethanol)
Alkylbenzene sulfonate
Anandamide
Barbiturates (e.g., pentobarbital, sodium thiopental)
Chlormethiazole
D12-116
Dihydropyridines (e.g., nicardipine)
Etomidate
Ginseng constituents (e.g., ginsenosides (e.g., ginsenoside-Rf))
Glutamic acid (glutamate)
Ivermectin
Ketamine
Neuroactive steroids (e.g., alfaxolone, pregnenolone (eltanolone), pregnenolone acetate, minaxolone, ORG-20599)
Nitrous oxide
Penicillin G
Propofol
Tamoxifen
Tetrahydrocannabinol
Triclofos
Tropeines (e.g., atropine, bemesetron, cocaine, LY-278584, tropisetron, zatosetron)
Volatiles/gases (e.g., chloral hydrate, chloroform, desflurane, diethyl ether (ether), enflurane, halothane, isoflurane, methoxyflurane, sevoflurane, toluene, trichloroethane (methyl chloroform), trichloroethylene)
Xenon
Zinc
Antagonists: 2-Aminostrychnine
2-Nitrostrychnine
4-Phenyl-4-formyl-N-methylpiperidine
αEMBTL
Bicuculline
Brucine
Cacotheline
Caffeine
Colchicine
Colubrine
Cyanotriphenylborate
Dendrobine
Diaboline
Endocannabinoids (e.g., 2-AG, anandamide (AEA))
Gaboxadol (THIP)
Gelsemine
iso-THAZ
Isobutyric acid
Isonipecotic acid
Isostrychnine
Laudanosine
N-Methylbicuculline
N-Methylstrychnine
N,N-Dimethylmuscimol
Nipecotic acid
Pitrazepin
Pseudostrychnine
Quinolines (e.g., 4-hydroxyquinoline, 4-hydroxyquinoline-3-carboxylic acid, 5,7-CIQA, 7-CIQ, 7-TFQ, 7-TFQA)
RU-5135
Sinomenine
Strychnine
Thiocolchicoside
Tutin
Negative modulators: Amiloride
Benzodiazepines (e.g., bromazepam, clonazepam, diazepam, flunitrazepam, flurazepam)
Corymine
Cyanotriphenylborate
Daidzein
Dihydropyridines (e.g., nicardipine, nifedipine, nitrendipine)
Furosemide
Genistein
Ginkgo constituents (e.g., bilobalide, ginkgolides (e.g., ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J, ginkgolide M))
Imipramine
NBQX
Neuroactive steroids (e.g., 3α-androsterone sulfate, 3β-androsterone sulfate, deoxycorticosterone, DHEA sulfate, pregnenolone sulfate, progesterone)
Opioids (e.g., codeine, dextromethorphan, dextrorphan, levomethadone, levorphanol, morphine, oripavine, pethidine, thebaine)
Picrotoxin (i.e., picrotin and picrotoxinin)
PMBA
Riluzole
Tropeines (e.g., bemesetron, LY-278584, tropisetron, zatosetron)
Verapamil
Zinc
NMDAR
See here instead.
Transporter(blockers)GlyT1
ACPPB
ALX-1393
ALX-5407 (NFPS)
AMG-747
ASP2535
BIIB-104 (PF-04958242)
Bitopertin (RG1678/RO4917838)
CP-802079
Ethanol (alcohol)
Glycyldodecylamide
GSK1018921
LY-2365109
ORG-24598
ORG-25935 (SCH-900435)
PF-02545920
PF-03463275
Sarcosine
SSR-103,800
SSR-504,734
GlyT2
Amoxapine
Ethanol (alcohol)
NAGly
Opiranserin (VVZ-149)
ORG-25543
VVZ-368

See also
Receptor/signaling modulators
GABA receptor modulators
GABAA receptor positive modulators
Ionotropic glutamate receptor modulators

vteIonotropic glutamate receptor modulatorsAMPAR
Agonists: Main site agonists: 5-Fluorowillardiine
Acromelic acid (acromelate)
AMPA
BOAA
Domoic acid
Glutamate
Ibotenic acid
Proline
Quisqualic acid
Willardiine; Positive allosteric modulators: Aniracetam
BIIB-104 (PF-04958242)
Cyclothiazide
CX-516
CX-546
CX-614
Farampator (CX-691, ORG-24448)
CX-717
CX-1739
CX-1942
Diazoxide
Hydrochlorothiazide (HCTZ)
IDRA-21
LY-392098
LY-395153
LY-404187
LY-451646
LY-503430
Mibampator (LY-451395)
Nooglutyl
ORG-26576
Oxiracetam
PEPA
Piracetam
Pramiracetam
S-18986
Tulrampator (S-47445, CX-1632)
Antagonists: ACEA-1011
ATPO
Becampanel
Caroverine
CNQX
Dasolampanel
DNQX
Fanapanel (MPQX)
GAMS
Kaitocephalin
Kynurenic acid
Kynurenine
Licostinel (ACEA-1021)
NBQX
PNQX
Selurampanel
Tezampanel
Theanine
Topiramate
YM90K
Zonampanel; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
Cyclopropane
Enflurane
Ethanol (alcohol)
Evans blue
GYKI-52466
GYKI-53655
Halothane
Irampanel
Isoflurane
Perampanel
Pregnenolone sulfate
Sevoflurane
Talampanel; Unknown/unsorted antagonists: Minocycline
KAR
Agonists: Main site agonists: 5-Bromowillardiine
5-Iodowillardiine
Acromelic acid (acromelate)
AMPA
ATPA
Domoic acid
Glutamate
Ibotenic acid
Kainic acid
LY-339434
Proline
Quisqualic acid
SYM-2081; Positive allosteric modulators: Cyclothiazide
Diazoxide
Enflurane
Halothane
Isoflurane
Antagonists: ACEA-1011
CNQX
Dasolampanel
DNQX
GAMS
Kaitocephalin
Kynurenic acid
Licostinel (ACEA-1021)
LY-382884
NBQX
NS102
Selurampanel
Tezampanel
Theanine
Topiramate
UBP-302; Negative allosteric modulators: Barbiturates (e.g., pentobarbital, sodium thiopental)
Enflurane
Ethanol (alcohol)
Evans blue
NS-3763
Pregnenolone sulfate
NMDAR
Agonists: Main site agonists: AMAA
Aspartate
Glutamate
Homocysteic acid (L-HCA)
Homoquinolinic acid
Ibotenic acid
NMDA
Proline
Quinolinic acid
Tetrazolylglycine
Theanine; Glycine site agonists: β-Fluoro-D-alanine
ACBD
ACC (ACPC)
ACPD
AK-51
Apimostinel (NRX-1074)
B6B21
CCG
D-Alanine
D-Cycloserine
D-Serine
DHPG
Dimethylglycine
Glycine
HA-966
L-687414
L-Alanine
L-Serine
Milacemide
Neboglamine (nebostinel)
Rapastinel (GLYX-13)
Sarcosine; Polyamine site agonists: Neomycin
Spermidine
Spermine; Other positive allosteric modulators: 24S-Hydroxycholesterol
DHEA (prasterone)
DHEA sulfate (prasterone sulfate)
Epipregnanolone sulfate
Plazinemdor
Pregnenolone sulfate
SAGE-201
SAGE-301
SAGE-718
Antagonists: Competitive antagonists: AP5 (APV)
AP7
CGP-37849
CGP-39551
CGP-39653
CGP-40116
CGS-19755
CPP
Kaitocephalin
LY-233053
LY-235959
LY-274614
MDL-100453
Midafotel (d-CPPene)
NPC-12626
NPC-17742
PBPD
PEAQX
Perzinfotel
PPDA
SDZ-220581
Selfotel; Glycine site antagonists: 4-Cl-KYN (AV-101)
5,7-DCKA
7-CKA
ACC
ACEA-1011
ACEA-1328
Apimostinel (NRX-1074)
AV-101
Carisoprodol
CGP-39653
CNQX
D-Cycloserine
DNQX
Felbamate
Gavestinel
GV-196771
Harkoseride
Kynurenic acid
Kynurenine
L-689560
L-701324
Licostinel (ACEA-1021)
LU-73068
MDL-105519
Meprobamate
MRZ 2/576
PNQX
Rapastinel (GLYX-13)
ZD-9379; Polyamine site antagonists: Arcaine
Co 101676
Diaminopropane
Diethylenetriamine
Huperzine A
Putrescine; Uncompetitive pore blockers (mostly dizocilpine site): 2-MDP
3-HO-PCP
3-MeO-PCE
3-MeO-PCMo
3-MeO-PCP
4-MeO-PCP
8A-PDHQ
18-MC
α-Endopsychosin
Alaproclate
Alazocine (SKF-10047)
Amantadine
Aptiganel
Argiotoxin-636
Arketamine
ARL-12495
ARL-15896-AR
ARL-16247
Budipine
Coronaridine
Delucemine (NPS-1506)
Dexoxadrol
Dextrallorphan
Dextromethadone
Dextromethorphan
Dextrorphan
Dieticyclidine
Diphenidine
Dizocilpine
Ephenidine
Esketamine
Etoxadrol
Eticyclidine
Fluorolintane
Gacyclidine
Ibogaine
Ibogamine
Indantadol
Ketamine
Ketobemidone
Lanicemine
Levomethadone
Levomethorphan
Levomilnacipran
Levorphanol
Loperamide
Memantine
Methadone
Methorphan
Methoxetamine
Methoxphenidine
Milnacipran
Morphanol
NEFA
Neramexane
Nitromemantine
Noribogaine
Norketamine
Orphenadrine
PCPr
PD-137889
Pethidine (meperidine)
Phencyclamine
Phencyclidine
Propoxyphene
Remacemide
Rhynchophylline
Rimantadine
Rolicyclidine
Sabeluzole
Tabernanthine
Tenocyclidine
Tiletamine
Tramadol; Ifenprodil (NR2B) site antagonists:
Besonprodil
Buphenine (nylidrin)
CO-101244 (PD-174494)
Eliprodil
Haloperidol
Isoxsuprine
Radiprodil (RGH-896)
Rislenemdaz (CERC-301, MK-0657)
Ro 8-4304
Ro 25-6981
Safaprodil
Traxoprodil (CP-101606); NR2A-selective antagonists: MPX-004
MPX-007
TCN-201
TCN-213; Cations: Hydrogen
Magnesium
Zinc; Alcohols/volatile anesthetics/related: Benzene
Butane
Chloroform
Cyclopropane
Desflurane
Diethyl ether
Enflurane
Ethanol (alcohol)
Halothane
Hexanol
Isoflurane
Methoxyflurane
Nitrous oxide
Octanol
Sevoflurane
Toluene
Trichloroethane
Trichloroethanol
Trichloroethylene
Urethane
Xenon
Xylene; Unknown/unsorted antagonists: ARR-15896
Bumetanide
Caroverine
Conantokin
D-αAA
Dexanabinol
Flufenamic acid
Flupirtine
FPL-12495
FR-115427
Furosemide
Hodgkinsine
Ipenoxazone (MLV-6976)
MDL-27266
Metaphit
Minocycline
MPEP
Niflumic acid
Pentamidine
Pentamidine isethionate
Piretanide
Psychotridine
Transcrocetin (saffron)
Unsorted: Allosteric modulators: AGN-241751

See also: Receptor/signaling modulators
Metabotropic glutamate receptor modulators
Glutamate metabolism/transport modulators

vteSymporter inhibitorsNa+-Cl−
Thiazides: Bendroflumethiazide
Chlorothiazide
Cyclopenthiazide
Cyclothiazide
Hydrochlorothiazide
Hydroflumethiazide
Methyclothiazide
Polythiazide
Trichlormethiazide; Others: Chlortalidone (chlorthalidone)
Metolazone
Na+-K+-Cl−
Bumetanide
Furosemide
See also: Receptor/signaling modulators
.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine





